Page 2

Claims 1-11. (cancelled)

Claim 12. (previously presented) A compound of Formula (I)

wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

U is hydrogen, halogen, an alkyl, heteroalkyl-, hetero-cycloalkyl-, heteroaryl- or heteroarylalkyl-group,

G-E is selected from the following groups,

wherein R' is F or a C<sub>1</sub>-C<sub>3</sub> alkyl group or G-E is part of an optionally substituted phenyl ring,

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>1</sub>-C<sub>4</sub>-alkenyl-, a C<sub>1</sub>-C<sub>4</sub>-alkynyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group, L-V-W is a group of formula CH=CH-CH, CH<sub>2</sub>-CH<sub>2</sub>-CH or CH<sub>2</sub>-CH=C, wherein the double bonds may be cis or trans isomers,

n is 0 or 2,

Page 3

X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heteroalkyl-, aralkyl- or heteroarylalkyl-group and

R<sup>3</sup> and R<sup>4</sup> independently from each other represent hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

Claim 13. (previously presented) A compound of claim 12, wherein A is a group of the formula -C (CH<sub>3</sub>) =CHR<sup>5</sup> or -CH=CHR<sup>5</sup>, wherein R<sup>5</sup> is a heteroaryl- or a heteroarylalkyl group.

Claim 14. (previously presented) A compound of claim 12, wherein A is a group of formula (II) or (III)

$$R^6 \longrightarrow R^6 \longrightarrow R^6$$

wherein Q is sulphur, oxygen or  $NR^7$ , wherein  $R^7$  is hydrogen, C1-C4 alkyl or  $C_1$ -C4 heteroalkyl, z is Nitrogen or CH and  $R^6$  is  $OR^B$ ,  $NHR^B$ , Cl-C4 alkyl, C1-C4 alkenyl, C1 C4 alkynyl or  $C_1$ -C6 heteroalkyl, wherein  $R^8$  is hydrogen,  $C_1$ -C4 alkyl or  $C_1$ -C4 heteroalkyl.

Claim 15. (previously presented) A compound of claim 12, wherein X is oxygen or NH.

BOS2 678317.1

Page 4

Claim 16. (previously presented) A compound of claim 12, wherein R<sup>1</sup> is methyl or ethyl.

Claim 17. (previously presented) A compound of claim 12, wherein R<sup>3</sup> and R<sup>4</sup> are methyl groups.

Claim 18. (previously presented) A compound of claim 12, wherein U is hydrogen, fluorine, methyl, trifluoro-methyl or COOH.

Claim 19. (previously presented) A compound of claim 14, wherein z is CH and Q is sulphur or oxygen.

Claim 20. (previously presented) A compound of claim 14, wherein R<sup>6</sup> is methyl, CH<sub>2</sub>OH or CH<sub>2</sub>NH<sub>2</sub>.

- Claim 21. (previously presented) A pharmaceutical composition comprising a compound of claim 12 a pharmacologically acceptable salt, a solvate, a hydrate or a prodrug thereof, and optionally carriers and/or adjuvants and/or diluents.
- Claim 22. (previously presented) A method for treating a patient suffering from or susceptible to cancer, comprising administering to the patient a compound of claim 12.
- Claim 23. (previously presented) The method of claim 22 wherein the patient is identified as suffering from cancer and selected for treatment for cancer, and the compound is administered to the identified and selected patient.

Page 5

Claim 24.

(previously presented)

A compound of claim 12 wherein A is a

thiazole.

Claim 25.

(cancelled)

Claim 26.

(new)

A compound of claim 12 wherein A is

Claim 27. (new) A compound of Formula (I)

wherein


A is a group of formula (II):

wherein Q is sulphur or oxygen, z is CH, and R<sup>6</sup> is CH<sub>3</sub>, CH<sub>2</sub>OH or CH<sub>2</sub>NH<sub>2</sub>,

Page 6

U is hydrogen,

G-E is selected from the following groups,



wherein R' is methyl,

 $R^1$  is  $C_1$ - $C_4$ -alkyl-,

L-V-W is a group of formula CH=CH-CH, CH<sub>2</sub>-CH<sub>2</sub>-CH or CH<sub>2</sub>-CH=C, wherein the double bonds may be cis or trans isomers,

n is 0 or 2,

X is oxygen or NH; and

R<sup>3</sup> and R<sup>4</sup> are each methyl,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

Claim 28. (new) A pharmaceutical composition comprising a compound of claim 27 a pharmacologically acceptable salt, a solvate, a hydrate or a prodrug thereof, and optionally carriers and/or adjuvants and/or diluents.

Claim 29. (new) A method for treating a patient suffering from or susceptible to cancer, comprising administering to the patient a compound of claim 27.

BOS2 678317.1

Page 7

Claim 30. (new) The method of claim 27 wherein the patient is identified as suffering from cancer and selected for treatment for cancer, and the compound is administered to the identified and selected patient.